In colon cancer cells, dipyridamole augmented the cytotoxicity of the MEK1/2 inhibitor, trametinib, and was used to treat unresectable or metastatic malignant melanomas with BRAF mutations [1] through the dual targeting of the HMGCS1 and MEK pathways [45]. This evidence concerns the gene MAP2K1 and melanoma.